南华生物医药股份有限公司 第十二届董事会第四次会议决议公告

Group 1 - The company held its 12th board meeting on October 24, 2025, via communication methods, with all 7 participating directors present, ensuring compliance with relevant laws and regulations [2] - The board reviewed and approved the proposal regarding the company's Q3 2025 report, which reflects the actual operating conditions for the first three quarters of 2025, with unanimous support from the directors [2] - The detailed content of the Q3 2025 report was disclosed on the same day through designated media [3] Group 2 - The meeting's resolutions, signed and sealed by the participating directors, along with the audit committee's decision from the 4th meeting of the 12th board, are available for review [4]